| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 13
| Issue : 2 | Page : 240-245 |
|
|
Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis
Ana Fernández Montes1, Paula González Villarroel2, Manuel Valladares Ayerbes3, Juan De la Cámara Gómez4, Guillermo Quintero Aldana5, Lidia Vázquez Tuñas6, Mercedes Salgado Fernández1, Mónica Jorge Fernández2
1 Departament of Medical Oncology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain
2 Departament of Medical Oncology, Complexo Hospitalario Universitario de Vigo, Pontevedra, Spain
3 Departament of Medical Oncology, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain
4 Departament of Medical Oncology, Complexo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain
5 Departament of Medical Oncology, Hospital Lucus Augusti, Lugo, Spain
6 Departament of Medical Oncology, Hospital de Pontevedra, Pontevedra, Spain
Correspondence Address:
Ana Fernández Montes
Departament of Medical Oncology, Complexo Hospitalario Universitario de Ourense, Servicio de Oncología Médica, E-32005 Ourense
Spain
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.181181
|
|
|
Background: Recent studies support the use of gemcitabine and nab-paclitaxel in adults with locally advanced unresectable or metastatic pancreatic adenocarcinoma although insufficient data are available on prognostic and predictive markers of response to treatment.
Objective: The objective of this study is to identify treatment response markers in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Materials and Methods: This is an observational, retrospective, and multicenter study. Sociodemographic, clinical, and therapeutic data were collected. Cox regression models were applied to determine associations.
Results: In total, 39 patients were included; 23.1% presented locally advanced pancreatic cancer and 76.9% metastatic disease. They received a mean of 6 ± 3 treatment cycles; 59% required dose reduction, 59% treatment delay, and 20.5% switched to a biweekly regimen. The overall response rate was 23% and the disease control rate was 81%. Median progression-free survival was 9 months and median overall survival (OS) was 15 months. A higher neutrophil/lymphocyte ratio (NLR) was significantly associated with lower OS. We reported Grades 1–4 nonhematological and hematological toxicities.
Conclusion: NLR is a useful prognostic factor for OS in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma treated with gemcitabine and nab-paclitaxel. Moreover, we suggest that a biweekly regimen is an option for certain groups of patients. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
